ESMO 2022 Conference Coverage
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 Study: Tislelizumab vs. Sorafenib as 1L Treatment for Unresectable HCC
By
ESMO 2022 Conference Coverage
FEATURING
Masatoshi Kudo
By
ESMO 2022 Conference Coverage
FEATURING
Masatoshi Kudo
104 views
September 19, 2022
Comments 0
Login to view comments.
Click here to Login
GI